Guardant Health (GH) PT Raised to $70 at Barclays
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- S&P 500 ends down; Apple dips ahead of quarterly report
- Apple beats quarterly estimates for profit and revenue
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops 7% as Iran signals openness to peace talks
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts GH Hot Sheet
Price: $170.73 --0%
Rating Summary:
30 Buy, 1 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 14 | New: 9
Rating Summary:
30 Buy, 1 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 14 | New: 9
Join SI Premium – FREE
Barclays analyst Luke Sergott raised the price target on Guardant Health (NASDAQ: GH) to $70.00 (from $60.00) while maintaining a Overweight rating.
You May Also Be Interested In
- BioMarin Pharmaceutical Inc. (BMRN) PT Lowered to $94 at Oppenheimer
- Clorox (CLX) PT Raised to $90 at Wells Fargo
- Guardant Health (GH) PT Raised to $210 at BTIG, remains Top Pick
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
